

Abigail A. Hazlett

Partner

Philadelphia

abigail.hazlett@troutman.com

D 215.981.4578



Abbey offers pragmatic counsel to clients, helping protect their businesses during turbulent times and navigating through their most significant and sensitive government and internal investigations.

OVERVIEW

Abbey provides strategic counsel to pharmaceutical, health care, technology, energy, and retail companies leading internal investigations and responding to government inquiries alleging individual or corporate misconduct, including violations of the False Claims Act (FCA), the Anti-Kickback Statute (AKS), and the Foreign Corrupt Practices Act (FCPA). Abbey takes a thoughtful and deliberate approach to investigating allegations of fraud, conflicts of interest, bribery, or other misconduct, helping each client make informed and practical decisions.

Her depth of experience in the False Claims Act — from the first knock on the door through declination decisions and to litigation — allows Abbey to position cases for a successful resolution. She regularly analyzes and argues the most complex and quickly evolving legal issues related to the FCA, keeping clients abreast of developments relevant to their legal and strategic goals.

Responsiveness and proactivity are central to Abbey's approach to client service, and she views advising on compliance best practices as a foundation of her practice. With a view toward practical and achievable objectives, Abbey counsels clients on how to structure their compliance programs and practices to align with Department of Justice and Securities & Exchange Commission expectations.

Abbey focuses her pro bono efforts on election protection, regularly managing the Pennsylvania hotline for the Lawyers' Committee for Civil Rights under the Law. She is also a board member of the Committee of Seventy, a nonpartisan organization that seeks to promote free and fair elections and good government, and she sits on the advisory board of the Temple Law School Center for Compliance and Ethics.

Before joining the firm, Abbey was a law clerk to the Hon. Harvey Bartle III of the U.S. District Court for the Eastern District of Pennsylvania.

REPRESENTATIVE MATTERS

- Defended several pharmaceutical companies in connection with government investigations alleging violations of the False Claims Act and the Anti-Kickback Statute, successfully obtaining government declinations and dismissals, and defending clients in subsequent *qui tam* actions.

- Conducted internal investigations on behalf of the boards of directors of publicly traded pharmaceutical and retail companies after allegations of financial fraud, conflicts of interest, bribery, and other corporate misconduct.
- Conducted internal investigations for publicly traded companies after allegations of C-suite misconduct, including data privacy violations, conflicts of interest, inappropriate personal relationships and discrimination.
- Advised and represented corporate clients that were victims of employee fraud and theft, successfully referring matters for federal prosecution.
- Successfully defended health care providers in government investigations alleging improper Medicare and Medicaid billings and violations of the False Claims Act.
- Defended construction manufacturers, suppliers, and developers in government investigations alleging violations of disadvantaged business enterprise (DBE) laws and regulations and advised the same clients on preventative compliance best practices.
- Advised pharmaceutical and retail clients on designing, implementing, and monitoring compliance programs that adhere to DOJ and SEC guidance.
- Advised pharmaceutical companies in connection with deferred prosecution and corporate integrity agreements following violations of the Foreign Corrupt Practices Act. The advisory role included investigating and developing remedial actions to deter future violations.

AWARDS

- *Best Lawyers in America®*: Criminal Defense: White-Collar (2026)
- *Legal 500 United States* for White Collar Criminal Defense (2019)

TOP AREAS OF FOCUS

- Business Litigation
- False Claims Act + Other Whistleblower Actions
- Fraud + Abuse Litigation + Investigations
- White Collar Litigation + Investigations

ALL AREAS OF FOCUS

- Business Litigation
- Due Diligence + Corporate Compliance
- False Claims Act + Other Whistleblower Actions
- Fraud + Abuse Litigation + Investigations
- Litigation + Trial
- White Collar Litigation + Investigations

PROFESSIONAL/COMMUNITY INVOLVEMENT

- Member, Law360 Pennsylvania Advisory Board (2024)
- Board member, Committee of Seventy
- Member, Temple Law School Center for Compliance and Ethics Advisory Board
- Core class, LEADERSHIP Philadelphia (2017-2018)

EDUCATION AND CERTIFICATIONS

EDUCATION

- University of Pennsylvania Carey Law School, J.D., *cum laude*, 2005, senior editor, *Journal of Constitutional Law*
- The Pennsylvania State University, B.A., 2001, political science

BAR ADMISSIONS

- Pennsylvania
- New York

COURT ADMISSIONS

- U.S. District Court, Eastern District of Pennsylvania
- U.S. District Court, Southern District of New York

CLERKSHIPS

- Hon. Harvey Bartle, III, U.S. District Court, Eastern District of Pennsylvania

SPEAKING ENGAGEMENTS

- Speaker, "[Ethical Oversight and Best Practices: AI Integration in Compliance Departments](#)," ACC Greater Philadelphia's Ethics & Compliance CLE Webinar, March 19, 2025.
- Speaker, "[2024 Election: What Every Pennsylvania Voter Should Know](#)," Troutman Pepper Webinar, October 28, 2024.
- Presenter, "[Federal and State Hospice Compliance](#)," Dragonfly Health Conference, Pittsburgh, PA, October 10, 2024.
- Panelist, "[Exploring Regulatory Actions and Trends](#)," Copay, Reimbursement and Access Congress, Philadelphia, PA, October 3, 2023.
- Moderator, "[Promoting LGBTQIA+ Diversity in the Workplace](#)," Troutman Pepper Webinar, June 24, 2021.
- Moderator, "[Mental Health, Organizational Risk, and Corporate Culture](#)," Temple University Center for Compliance and Ethics, May 12, 2021.

PUBLICATIONS

- Co-author, "[With New Tariffs, Recent Settlements May Foreshadow Future DOJ Enforcement](#)," *Troutman Pepper Locke*, August 8, 2025.
- Co-author, "[Trump Pauses FCPA Enforcement: Implications for Corporate Compliance Strategies](#)," *Troutman Pepper Locke*, February 18, 2025.
- Co-author, "[The Stick and the Carrot: DOJ Continues to Eye Corporate Crimes, While Encouraging Prompt Self-Disclosures of Misconduct Discovered During M&A](#)," *Troutman Pepper*, November 8, 2023.
- Podcast, "[Navigating Workplace Confidentiality and Compliance When Government Agents Come Calling](#)," *Hiring to Firing Podcast*, October 17, 2023.
- Co-author, "[7 Common Compliance Pitfalls for Multistate Pharmacies](#)," *Law360*, October 3, 2023.
- Co-author, "[Multistate Pharmacies: A Prescription for Navigating the Regulatory Maze](#)," *Troutman Pepper*, September 13, 2023.
-

Co-author, "Does the Government Retain Control of False Claims Act Cases?," *Troutman Pepper*, June 21, 2023.

- Co-author, "Conducting Corporate Investigations in an Era of Individual Accountability: New Guidance on Corporate Criminal Enforcement," *Troutman Pepper*, October 4, 2022.
- Co-author, "Record Year for False Claims Act Settlements," *Troutman Pepper*, March 31, 2022.
- Co-author, "DOJ Reintroduces Corporate Compliance Monitors," *Troutman Pepper*, November 16, 2021.
- Co-author, "A Difference of Opinion Remains: The Third Circuit's Rejection of an 'Objective Falsity' Requirement for FCA Liability Stands After the Supreme Court Denies Certiorari," *Troutman Pepper*, March 2, 2021.
- Co-author, "DOJ and Compliance: Great Expectations and Even Greater Consequences Ahead," *Troutman Pepper*, January 28, 2021.

MEDIA COMMENTARY

- Quoted, "Keeping Government Investigations From Rattling Employees," *Legal Dive*, October 30, 2023.
- Troutman Pepper Featured, "From Courts to Polls: BigLaw Turns Out to Protect the Vote," *Law360*, November 8, 2022.
- Mentioned, "Mental Health, Organizational Risk, and Corporate Health During COVID-19: Webinar Review," *The Temple 10-Q*, July 16, 2021.